**Supplamentary Table 2 –** Group features of Low responders participants (IgG<4000) versus high responders (IgG>4000)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | IgG<4000 | IgG>4000 | p |
|  |  | n = 36 | n = 118 |  |
| Group sample (%) | Non-Oncology | 8 ( 22.2) | 38 ( 32.2) | 0.534 |
|  | Non-Oncology + Cannabis | 5 ( 13.9) | 16 ( 13.6) |  |
|  | Oncology | 18 ( 50.0) | 44 ( 37.3) |  |
|  | Oncology + Cannabis | 5 ( 13.9) | 20 ( 16.9) |  |
| Days dose to IgG test (mean (SD)) |  | 73.11 (19.37) | 74.00 (19.32) | 0.81 |
| IgG (AU/ml) (mean (SD)) |  | 2113.74 (1109.15) | 17331.91 (12496.37) | <0.001 |
| IgG response (%) | IgG<4000 | 36 (100.0) | 0 ( 0.0) | <0.001 |
|  | IgG>4000 | 0 ( 0.0) | 118 (100.0) |  |
| Gender (%) | Female | 20 ( 55.6) | 65 ( 55.1) | 1 |
|  | Male | 16 ( 44.4) | 53 ( 44.9) |  |
| Age (mean (SD)) |  | 65.00 (11.45) | 60.60 (14.09) | 0.09 |
| Cancer type (%) | Bladder | 2 ( 8.7) | 0 ( 0.0) | 0.286 |
|  | Breast | 9 ( 39.1) | 21 ( 32.8) |  |
|  | Colon | 4 ( 17.4) | 7 ( 10.9) |  |
|  | Kidney | 0 ( 0.0) | 2 ( 3.1) |  |
|  | Lungs | 1 ( 4.3) | 7 ( 10.9) |  |
|  | Lymphoma | 0 ( 0.0) | 4 ( 6.2) |  |
|  | Melanoma | 1 ( 4.3) | 8 ( 12.5) |  |
|  | Pancreas | 1 ( 4.3) | 2 ( 3.1) |  |
|  | Prostate | 0 ( 0.0) | 1 ( 1.6) |  |
|  | Sarcoma | 1 ( 4.3) | 1 ( 1.6) |  |
|  | Stomach | 3 ( 13.0) | 5 ( 7.8) |  |
|  | Urinary bladder | 0 ( 0.0) | 5 ( 7.8) |  |
|  | Uterus | 1 ( 4.3) | 1 ( 1.6) |  |
| Cancer stage (%) | Localized | 6 ( 26.1) | 21 ( 32.8) | 0.737 |
|  | Metastatic | 17 ( 73.9) | 43 ( 67.2) |  |
| THC.CBD (%) | CBD rich | 3 ( 30.0) | 9 ( 25.0) | 1 |
|  | THC rich | 7 ( 70.0) | 27 ( 75.0) |  |
| Cannabis use frequency (%) | Daily | 9 ( 90.0) | 31 ( 86.1) | 1 |
|  | Occasional | 1 ( 10.0) | 5 ( 13.9) |  |
| Cannabis (gr/month) (mean (SD)) |  | 31.00 (19.12) | 30.00 (16.56) | 0.871 |
| Cannabis (number of daily sessions) (mean (SD)) |  | 1.10 (0.32) | 1.19 (0.40) | 0.497 |